Skip to content

Author

E. Sakaida

We have 4 of 299 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Oct 2026

A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas

T follicular helper cell lymphomas (TFHL) harbor activating T cell receptor (TCR) signaling mutations and epigenetic alterations, such as TET2 mutations. Here, we conduct a multi-center, single-arm, phase 2 trial of the tyrosine kinase inhibitor dasatinib in patients with relapsed/refractory TFHLs (jRCT2031190079). The...

S. Suma, M. Sakata-Yanagimoto, Y. Suehara et al. · 0 citations
Open access Sep 2026

Epstein-Barr virus-associated chromatin activation and enhancer engagement in T/NK-cell lymphoproliferative diseases.

A model in which EBV contributes to oncogenic transcriptional programs in these diseases by coupling three-dimensional chromatin reorganization and regulatory element activation to physical interactions with the host genome is supported.

Shuntaro Isogai, Atsushi Okabe, Kazusuke Tanaka et al. · 0 citations
Open access Aug 2026

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.

Tatsuya Konishi, W. Kitamura, Shohei Mizuno et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.